UY34479A - Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales - Google Patents

Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales

Info

Publication number
UY34479A
UY34479A UY0001034479A UY34479A UY34479A UY 34479 A UY34479 A UY 34479A UY 0001034479 A UY0001034479 A UY 0001034479A UY 34479 A UY34479 A UY 34479A UY 34479 A UY34479 A UY 34479A
Authority
UY
Uruguay
Prior art keywords
tripanosomiasis
animals
treatment
solution
pharmaceutical composition
Prior art date
Application number
UY0001034479A
Other languages
English (en)
Spanish (es)
Inventor
Gonzalez Cordero Auristela
Ochoa Roviro Alberto
Original Assignee
Invest Farmaceuticas Y Veterinarias S L
Reveex De Venezuela C A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Invest Farmaceuticas Y Veterinarias S L, Reveex De Venezuela C A Lab filed Critical Invest Farmaceuticas Y Veterinarias S L
Publication of UY34479A publication Critical patent/UY34479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communication Control (AREA)
UY0001034479A 2012-01-24 2012-11-29 Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales UY34479A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230092A ES2416004B1 (es) 2012-01-24 2012-01-24 Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales.

Publications (1)

Publication Number Publication Date
UY34479A true UY34479A (es) 2013-07-31

Family

ID=46963763

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034479A UY34479A (es) 2012-01-24 2012-11-29 Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales

Country Status (16)

Country Link
AP (1) AP2014007798A0 (pt)
AR (1) AR089037A1 (pt)
BR (1) BR112014016926A8 (pt)
CL (1) CL2014001780A1 (pt)
CO (1) CO6990714A2 (pt)
CR (1) CR20140278A (pt)
DO (1) DOP2014000161A (pt)
EC (1) ECSP14010152A (pt)
ES (1) ES2416004B1 (pt)
GT (1) GT201400159A (pt)
MA (1) MA35868B1 (pt)
MX (1) MX2014008172A (pt)
NI (1) NI201400075A (pt)
PE (1) PE20141472A1 (pt)
UY (1) UY34479A (pt)
WO (1) WO2013110830A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024008B (en) * 1978-06-28 1983-02-16 Merck & Co Inc Compositions for treating trypanosomiasis infections
GB8805286D0 (en) * 1988-03-05 1988-04-07 Schering Agrochemicals Ltd Trypanocides
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
DE19854143A1 (de) * 1998-11-24 2000-05-25 Chambord Ltd Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung
FR2819188B1 (fr) * 2001-01-08 2003-03-14 Virbac Sa Compositions pulverulentes ou granulees hydrosolubles, a base de phenanthridines et leurs utilisations
AR060926A1 (es) * 2007-05-14 2008-07-23 Ciriaco Quiroga Solucion anestesica transparente de propofol, con baja irritacion venosa.
KR20080102010A (ko) * 2007-05-17 2008-11-24 대원제약주식회사 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
WO2011042565A2 (en) * 2009-10-09 2011-04-14 Instituut Voor Tropische Geneeskunde Antiprotozoal activity

Also Published As

Publication number Publication date
DOP2014000161A (es) 2014-08-15
AP2014007798A0 (en) 2014-07-31
CO6990714A2 (es) 2014-07-10
NI201400075A (es) 2015-04-13
BR112014016926A2 (pt) 2017-06-13
MA35868B1 (fr) 2014-12-01
ECSP14010152A (es) 2015-08-31
WO2013110830A1 (es) 2013-08-01
AR089037A1 (es) 2014-07-23
ES2416004B1 (es) 2014-01-28
BR112014016926A8 (pt) 2017-07-04
GT201400159A (es) 2015-11-19
MX2014008172A (es) 2014-10-06
CR20140278A (es) 2014-12-02
CL2014001780A1 (es) 2014-10-24
ES2416004A1 (es) 2013-07-29
PE20141472A1 (es) 2014-11-05

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20150316A (es) Compuestos y sus métodos de empleo
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34885A (es) Proteínas de unión anti-mesotelina
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
ECSP14030779A (es) Inhibidores del nampt
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CR20140367A (es) Inhibidores de iap
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
UY34579A (es) Dispositivo de inhalación para fármacos en polvo

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211216